- Trial Phase
- Approved
- Time to Market
- Already approved (December 2023) for hATTR-PN. ATTR-CM label expansion now appears unlikely after the Phase 3 failure.
- Why 3/10
- Eplontersen is already FDA-approved and commercializing for hATTR-PN (Dec 2023). The next major catalyst — the Phase 3 CARDIO-TTRansform readout in ATTR-CM — just failed on July 9, 2026, killing the label-expansion opportunity. No hard dated binary catalyst remains for this specific drug in the next ~12 months, limiting share-price impact to ongoing commercial execution and royalty reporting.
The ATTR-CM expansion (a vastly larger addressable market than hATTR-PN) just failed, removing a major bull thesis for IONS. The approved hATTR-PN business continues generating ~$49M/yr in royalties for Ionis, but the stock's ~20% selloff on July 9 reflects the lost upside. Watch for whether the prespecified monotherapy subgroup (HR 0.71) generates any salvage strategy with regulators, though analysts are skeptical.
Price Chart
Executive Summary
Eplontersen (branded Wainua in the US, Wainzua in the EU) is an FDA-approved antisense oligonucleotide from Ionis Pharmaceuticals (IONS) and partner AstraZeneca for treating hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN). It generated $212M in global 2025 sales, with Ionis receiving $49M in royalties. The drug's pivotal Phase 3 CARDIO-TTRansform trial for the much larger ATTR cardiomyopathy (heart) indication failed its primary endpoint on July 9, 2026, causing IONS stock to drop ~20%. A prespecified monotherapy subgroup showed a nominally significant benefit, but the overall miss was a major setback that boosts competitor drugs from Alnylam (Amvuttra) and BridgeBio (Attruby). The approved hATTR-PN business continues, but the largest value-driving opportunity is now off the table.
How It Works
Eplontersen is a ligand-conjugated antisense oligonucleotide (LICA) — a synthetic RNA molecule that homes to the liver and blocks production of transthyretin (TTR) protein. In hereditary ATTR amyloidosis, abnormal TTR protein builds up and damages nerves (hATTR-PN) or heart muscle (ATTR-CM). By reducing TTR production at its source, eplontersen slows disease progression. It is self-administered via monthly subcutaneous injection using an auto-injector.
Trial Status
FDA-approved December 2023 for hATTR-PN based on Phase 3 NEURO-TTRansform results showing 81.7% serum TTR reduction and significant improvements in neuropathy and quality of life. The Phase 3 CARDIO-TTRansform trial (1,432 patients) for the larger ATTR-CM indication failed its primary composite endpoint of CV mortality and recurrent CV events on July 9, 2026. A prespecified monotherapy subgroup showed a nominally significant HR of 0.71, but patients on background TTR stabilizers saw no benefit — analysts doubt this supports regulatory filing.
The Two-Sided Case
Upcoming Catalysts
- Ongoing NEURO-TTRansform open-label extension data for hATTR-PN (safety/long-term efficacy updates)
- Potential regulatory discussions on monotherapy subgroup data from CARDIO-TTRansform — though analysts view an ATTR-CM filing as unlikely
- Quarterly commercial sales reports for Wainua/Wainzua
- Ionis investor updates: other pipeline catalysts (bepirovirsen PDUFA Oct 2026, zilganersen PDUFA Sep 2026, olezarsen sNDA PDUFA Jun 2026) are more material near-term drivers for IONS
Source Filing
The SecBot filing or press-release report that triggered this drug report:
IONIS PHARMACEUTICALS INC 8-K IONS ·Originating report